In conclusion, we observed that high MCL1 gain was poorer prognostic factor for DFS and OS in later stage of ESCC patients (with lymph node metastasis or stage III-IVa) 29 months later. Here, MCL1 is linked to metastatic malignant neoplasm in the lymph nodes.